NEW YORK (360Dx) – PerkinElmer said today that it has received 510(k) clearance from the US Food and Drug Administration for its NeoLSD MSMS kit, an in vitro diagnostic that screens for the six most common lysosomal storage disorders in newborn babies.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.